1 / 42

CNS Malignancies for internists

CNS Malignancies for internists. CNS Malignancy. Primary brain tumors 2% of all cancers Mortality 4.6/100,000 person years Incidence increasing Brain mets can occur in up to 40% of all solid tumors PCNSL incidence increasing. Clinical presentation. Headache Seizure

sapphire-ilithya
Download Presentation

CNS Malignancies for internists

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CNS Malignanciesfor internists

  2. CNS Malignancy • Primary brain tumors • 2% of all cancers • Mortality 4.6/100,000 person years • Incidence increasing • Brain mets can occur in up to 40% of all solid tumors • PCNSL incidence increasing

  3. Clinical presentation • Headache • Seizure • Focal neurologic deficit • Confusion • Memory loss • Personality change • Nausea/vomiting

  4. Differential Diagnosis • Primary brain tumor • Malignant • Glioma • Lymphoma • Benign meningioma, adenoma, schwannoma • Metastatic brain tumor • Vascular • Cerebellar hemorrhage: vascular anomaly, hypertensive, intratumoral • Cerebellar infarct: embolic, thrombotic • Infection: • Abcess, virus, progressive multifocal leukoencephalopathy • Inflammatory: • Multiple sclerosis • Post-infectious encephalomyelitis

  5. T1 Contrast

  6. Imaging • Diagnosis • CT • MRI • SPECT • Treatment planning • Functional MRI • Monitoring response • Diffussion-weighted, diffusion tensor, dynamic-contrast-enhanced, perfusion

  7. Additional work-up • History and physical for evidence of an extracranial primary or other disease • Appropriate imaging to look for that primary • Avoid corticosteroids if lymphoma or infection is suspected

  8. Neurosurgery • Who should get a biopsy? • Diagnosis in question • Results will influence management • Do not need immediate relief of symptoms • Non resectable; critical location • Suspect low-grade glioma or PCNSL • Alternate diagnosis? • 11% of 56 enrolled on surgery trial had alternate diagnosis on central pathology review Patchell RA, et al., A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990.

  9. Primary brain tumors

  10. Primary Brain Tumors • Malignant gliomas • 70% of primary brain malignancy • 14,000 cases/year in US • Incidence increasing, esp. in elderly • 40% more common in men • Twice as common in whites • Median age 64 (GBM) or 45 (AA) • Others

  11. Primary Brain Tumors • Etiology • Ionizing radiation risk factor • No association with head injury, food, occupation, electromagnetic fields, cell phones • Reduced risk with atopy, high IgE levels • Family history • 5% are familial, most without known cause • NF type 1 or 2, Li-Fraumeni syndrome, Turcot syndrome

  12. Initial medical management • Corticosteroids: oral dex 4-16 mg/day • Anti-epileptics: leviteracitam • VTE treatment/prophy • Stimulants: modafenil, methylphenidate, donepezil, memantine • Anti depressants

  13. CORTICOSTEROIDS ANTI EPILEPTICS VTE TREATMENT/PROPHY ANTI NEOPLASTIC THERAPY STIMULANTS ANTI DEPRESSANTS

  14. Anti-neoplastic therapy • Surgery: maximal resection • Radiotherapy: WBRT • Chemotherapy: TMZ Stupp R, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96.

  15. Molecular genetics • MGMTpromotormethylation (GMB) • Decreased DNA repair activity • Increased susceptibility to TMZ • 1p 19q deletion (anaplasticoligodendrogliomas and anaplasticoligoastrocytomas) • Increased sensitivity to PCV • Reason unknown

  16. Brain metastases

  17. Brain metastases • Rates • Represent >50% of all intracranial tumors • 40% of cancers will develop brain mets • Common tumors • Lung • Breast • melanoma • Sites • 90-95% solid parenchymal, 5-10% meningeal • 37-50% solitary, 50-63% multiple

  18. Brain Metastases Prognosis • 1-6 month survival • Improved by (RTOG prognostic index): • Age <65 • KPS >70 • Controlled primary w/out extracranialmets • Other favorable factors: • Solitary met • Response to corticosteroids • Longer disease-free interval • Breast cancer diagnosis

  19. Brain metastases Differential diagnosis • Primary brain tumor • Infection • Inflammation • Demyelinating disorders • Infarction • Radiation necrosis

  20. Brain Metastases • Surgery + WBRT >>> Surgery Reduced brain recurrance and neuro death • Surgery + WBRT === SRS +/- WBRT • But you must know: • radiosensitivity of the tumor • # of tumors • Accessibility for resection

  21. Leptomeningeal metastases

  22. Leptomeningeal Metastases • Diagnosis: • MRI 76% sen, 77% spec (false pos with intracranial hypotension, infection, connective tissue disease, deymelinating disease) • CSF 90% sen, 100% spec • Prognosis: <3 months • Treatment: • Radiotherapy for bulky disease or CSF flow obstruction • IT chemotherapy through Ommaya: • MTX • Lipsomalcytarabine • Thiotepa

  23. PCNSL

  24. PCNSL • Rare: 2.7% of all primary brain tumors • Incidence increased 3-fold from 1978-84 • Immunocompetent: • male>female • age >60 • Immunodeficiency is only risk factor • HIV 3,600-fold increased risk • CD4+ cell count <50 cells/uL highest risk

  25. PCNSL • Site • 65% solitary • 38% in hemispheres • 20% occular involvement • Histology • DLBCL (90%) • Low-grade lymphoma • Burkitt’s lymphoma • T-cell lymphoma

  26. PCNSL • Imaging: MRI preferred • CSF: cytology, flow, IgH PCR • Eye exam • Rule out systemic disease • Rule out testicular and bone marrow involvement • Biopsy is essential

  27. Non con T2 CSF -- high WBC >7 cells/uL -- high protein -- low glucose Initial positive in only 15% Con T1

  28. PCNSL • International Extranodal Lymphoma Study Group • Age >60 • ECOG PS >1 • Elevated LDH • High CSF protein • Deep location

  29. PCNSL • Chemotherapy: High dose MTX + IT MTX • Radiotherapy: WBRT for those <60

  30. Memory failure, gait ataxia, incontinence

  31. references

More Related